DNA Methylation Analysis
Detects epigenetic changes that occur early in cancer development, before tumors become visible on traditional imaging.
Tissue-of-Origin Prediction
Advanced algorithms identify not just the presence of cancer, but also predict which organ system which is affected.
One Sample Six Cancers
Single blood test screens for six major cancer types simultaneously, providing comprehensive coverage with one blood draw.
Early-Stage Sensitivity Limits
Early tumors release very little
circulating tumor DNA (ctDNA)
Methylated cfDNA is released by
both tumor and surrounding cells
Methylation is detectable at
very low ctDNA levels
The Science Behind Sentinel‑6
Epigenetic Modifications
Sentinel‑6™ examines 70,000 molecular switches (CpG Islands) to detect abnormal gene silencing, enabling earlier and more precise cancer detection.
Tissue‑of‑Origin Prediction
After analyzing 70,000 molecular switches, data is processed using Machine Learning algorithms to detect early changes and predict the cancer’s origin.
Detect six major cancers early with Sentinel-6™
Sentinel-6™ screens for cancers that often lack routine screening options and are difficult to detect early.
Lung Cancer
Leading cause of cancer deaths
Liver Cancer
Often detected at late stages
Esophageal Cancer
Poor prognosis when detected late
Ovarian Cancer
No routine screening available
Pancreatic Cancer
Highly aggressive, early detection crucial
Colorectal Cancer
Supplement to existing screening
Who Should Consider Sentinel-6™
Experience the benefits of next-generation cancer screening technology.
Age 40-75
Adults in the optimal age range for cancer screening
Current/Former Smokers
Individuals with smoking history
at higher cancer risk
Family History
Those with family history of cancer or genetic risk factors
Chronic Conditions
Individuals with chronic hepatitis B/C, obesity, or diabetes
Limited Screening Access
Those without routine screening for pancreatic, liver, or ovarian cancer
Proactive Health
Health-conscious individuals seeking comprehensive cancer screening
Why Early Detection Matters
90
Cancer survival rate when detected at Stage 1
5
More treatment options available with early detection
50
Reduction in treatment costs with early intervention
Validated Performance & Studies
Sentinel-6™ is powered by OverC® technology and has been rigorously tested across multiple clinical studies with proven results.
98.9
Overall Specificity
Distinguishes healthy from cancer patients with 98.9 % accuracy.
69.1
Average Sensitivity
Detects cancer in 7/10 cases, at Stages (I-III).
83-92
Tissue-of-Origin Accuracy
Precise identification of cancer location.
4700
Participants Tested
Validated across multiple
clinical studies.
Completed Studies: Sensitivity and Specificity
Sensitivity
Specificity
Percentage (%)
Detection Limits of ctDNA-Based Assays
Approx. Limit of Detection (LOD95)
Adapted from Moding et al., Cancer Discovery (2021)
Powered by OverC® Technology
Sentinel‑6™ uses advanced OverC® technology from Burning Rock Biotech with exceptional precision and reliability, backed by FDA approval and CE‑IVD certification for global diagnostic use.
Breakthrough Device Designation
Advanced Detection Platform
European Certification
How It Works
01
Registration
Complete your
registration and
health assessment
questionnaire.
02
Sample Collection
Simple blood draw
performed by
trained healthcare
professionals.
03
Sample Delivery
Your sample is
securely transported
to the testing
laboratory.
04
Cancer Signal Testing
Advanced OverC®
technology analyzes
your blood for cancer
signals.
05
Report Generation
Comprehensive analysis
with personalized
oncology treatment
guidance.
Ready to Take Control of Your Health?
Join thousands of people who have chosen proactive cancer screening. Early detection saves lives, and it could save yours too.
Schedule Online
Book your appointment in under 2 minutes
Visit Lab
Quick blood draw at convenient locations
Get Results
Comprehensive report with next steps
Why Choose Our Test?
Experience the benefits of next-generation cancer screening technology.
Peace of Mind
Know your cancer risk status with confidence and take control of your health.
Better Outcomes
Early detection dramatically improves treatment success rates and survival.
Time Advantage
Detect cancer years before symptoms appear or traditional screening methods.
Cost Effective
Reduce long-term healthcare costs through early intervention and prevention.
Family Protection
Protect your family by understanding your genetic predisposition to cancer.
Quick & Easy
Simple blood test with fast results – no complex procedures required.
Enhancing Cancer Care in Germany
Integration Into German Cancer Screening Programs
Sentinel‑6™ complements existing G-BA screening by targeting cancers without routine tests in Germany (pancreatic, liver, ovarian). Ongoing pilot studies in Berlin and Munich will inform integration into GKV preventive models and support G-BA reimbursement discussions.
Next Steps for Healthcare Providers
- Pilot programs available for KVB-registered practices
- Integration with integrative clinics
- Collaboration on diagnostic pathways
- Second-opinion services and research studies
Inquiries:
beat.cancer@precimmo.com
Why This Matters
- Assess turnaround time and patient compliance
- Evaluate positive predictive value in real-world German settings
- Provide data-driven economic evidence for GKV and private insurers
- Generate cost-benefit and ROI analysis
